InvestorsHub Logo
Followers 47
Posts 5233
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Monday, 11/02/2020 7:34:09 AM

Monday, November 02, 2020 7:34:09 AM

Post# of 8928
$CAPR globenewswire.com/news-rele...

https://www.globenewswire.com/news-release/2020/11/02/2118122/0/en/Sanofi-offers-to-acquire-Kiadis-a-clinical-stage-company-developing-cell-based-immunotherapy-products.html

$SNY Sanofi offers to acquire Kiadis for €308 million

Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK cells from a healthy donor.

KNK-ID-101 is a program evaluating the properties of K-NK cells and their suitability to fight SARS-CoV-2 and the option to develop K-NK cells as a post-exposure pre-emptive therapy for COVID-19 in high risk patients. Kiadis plans to initiate a phase 1/2a clinical trial evaluating use of K-NK cells to treat COVID-19 patients with government grant funding.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CAPR News